TRVI
Trevi Therapeutics, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom -1.5% · netto nieuwe posities 0.0% · formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 3.53M | $50.51M | n/a | n/a |
| Q2 2026 | 73 | -1 | 67.22M | $1.24B | +7 | −8 |
| Q1 2026 | 77 | +2 | 59.43M | $710.63M | +8 | −6 |
| Q4 2025 | 75 | 0 | 58.45M | $731.74M | +1 | −1 |
| Q3 2025 | 18 | 0 | 44.17M | $404.20M | n/a | n/a |
| Q2 2025 | 15 | 0 | 25.58M | $139.93M | +1 | −1 |
| Q1 2025 | 12 | 0 | 12.85M | $80.81M | +1 | −1 |
| Q4 2024 | 12 | +4 | 15.26M | $62.88M | +4 | n/a |
| Q3 2024 | 7 | +3 | 5.91M | $19.73M | +3 | n/a |
| Q2 2024 | 4 | n/a | 5.62M | $16.74M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 6.50M | +97.0% | $81.38M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 2 | The Vanguard Group ✦ (passief) | 6.43M | +10.4% | $80.56M | 0.0% | ▲ Add | 3 | SEC ↗ ×5 |
| 3 | Wellington Management ✦ | 3.40M | +4.6% | $42.62M | 0.0% | ▲ Add | 4 | SEC ↗ ×7 |
| 4 | State Street Global Advisors ✦ (passief) | 2.44M | +9.7% | $30.49M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 5 | Raymond James Financial Inc | 1.77M | n/a | $22.12M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 6 | Bank Of America Corp /De/ | 1.09M | n/a | $13.71M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 7 | Goldman Sachs Group ✦ | 1.06M | +34.2% | $13.23M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | Morgan Stanley ✦ | 1.05M | -75.6% | $13.15M | 0.0% | ▼ Trim | 2 | SEC ↗ ×8 |
| 9 | Charles Schwab Investment… | 836.80K | n/a | $10.48M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Northern Trust Corp | 761.97K | n/a | $9.54M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 11 | Barclays Plc | 582.65K | n/a | $7.29M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Invesco Ltd. | 498.93K | n/a | $6.25M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 13 | Ameriprise Financial Inc | 324.17K | n/a | $4.06M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Sei Investments Co | 147.94K | n/a | $1.85M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | UBS AM, a distinct business unit of… | 140.73K | n/a | $1.76M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 16 | Citigroup Inc | 123.50K | n/a | $1.55M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 17 | State Of Wisconsin Investment Board | 120.57K | n/a | $1.51M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Wells Fargo & Company/Mn | 101.28K | n/a | $1.27M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 19 | Legal & General Group Plc | 81.67K | n/a | $1.02M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 20 | Tudor Investment Corp Et Al | 68.48K | n/a | $857,382 | 0.0% | n/c | 1 | SEC ↗ |
| 21 | JPMorgan Chase ✦ | 59.48K | -49.4% | $744,627 | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 22 | T. Rowe Price ✦ | 50.27K | +7.3% | $630,000 | 0.0% | ▲ Add | 7 | SEC ↗ |
| 23 | Franklin Resources Inc | 49.88K | n/a | $624,472 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 24 | Dimensional Fund Advisors Lp | 36.51K | n/a | $457,105 | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Stifel Financial Corp | 28.29K | n/a | $354,166 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 26 | New York State Common Retirement… | 27.77K | n/a | $347,618 | 0.0% | n/c | 1 | SEC ↗ |
| 27 | National Bank Of Canada /Fi/ | 2.97K | n/a | $37,087 | 0.0% | n/c | 1 | SEC ↗ |
| 28 | Pnc Financial Services Group, Inc. | 999 | n/a | $12,507 | 0.0% | n/c | 1 | SEC ↗ |
| 29 | Jones Financial Companies Lllp | 620 | n/a | $7,762 | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Us Bancorp \De\ | 4 | n/a | $50 | 0.0% | n/c | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 198 houders, 134.86M aandelen, $1.61B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Director · 18.32K aand · $276,464
Director · 100 aand · $1,588
Director · 20.95K aand · $316,166
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie